Macon, GANCT07869836Now EnrollingIRB Ready

Urothelial Cancer Clinical Trial in Macon, GA

Access cutting-edge urothelial cancer treatment through this phase 3 clinical trial at a research site in Macon. Study-provided care at no cost to qualified participants.

Sponsored by SystImmune Inc.

Quick Self-Assessment

See if you qualify for this Macon location

Preparing your pre-screening questions…

Expert Care in Macon

Access urothelial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related urothelial cancer treatment provided free

Apply for This Macon Location

Check if you qualify for this urothelial cancer clinical trial in Macon, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Macon

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Macon site if eligible
  4. 4Begin participation

About This Urothelial Cancer Study in Macon

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Sponsor: SystImmune Inc.

Who Can Participate

Inclusion Criteria

Histologically or cytologically documented metastatic or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the renal pelvis, ureter, bladder, or urethra. Minor histologic variants (ie, \<50% overall) are acceptable, provided that TCC is the dominant histology.
Disease progression or recurrence during or following anti-PD-(L)1-based therapy.
Fresh biopsy or archival tumor samples.
Documented HER2 expression by central laboratory testing.
Eligible to receive carboplatin or cisplatin in combination with gemcitabine.
At least 1 measurable lesion based on RECIST v1.1.
An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
Adequate organ function.
Adequate coagulation parameters.

Exclusion Criteria

Prior topoisomerase inhibitor-based ADC therapy.
Primary tumors in the central nervous system (CNS), active or untreated CNS metastases, or carcinomatous meningitis.
Bladder cancers with small cell histology.
Other prior or concurrent malignancies except for certain localized cancers or low-grade prostate cancer (if approved by sponsor), or other malignancy treated with curative intent with a disease-free interval of at least 3 years.
Prior history of clinically significant bleeding, or perforation of the gastrointestinal tract within 6 months of randomization.
Active autoimmune diseases and inflammatory diseases.
History of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
Advanced/clinically significant lung disease (eg, poorly controlled chronic obstructive pulmonary disease or asthma, restrictive lung disease, or pulmonary hypertension) within 6 months prior to randomization.
Known human immunodeficiency virus infection.
Active hepatitis B virus (HBV) infection.
Active hepatitis C virus (HCV) infection.
Active or latent tuberculosis.
Other protocol-specified inclusion/ exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Macon?

Yes, this clinical trial (NCT07869836) has an active research site in Macon, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Urothelial Cancer Treatment Options in Macon, GA

If you're searching for urothelial cancer treatment options in Macon, GA, this clinical trial (NCT07869836) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Macon research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced urothelial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all urothelial cancer clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Macon, GA

See all bladder cancer clinical trials recruiting in Macon — not just this study.

Browse Bladder Cancer Trials in Macon →

Browse More Trials by Condition

Bladder Cancer TrialsAll Conditions →

Ready to Join in Macon?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Macon, GA